Search results
Results from the WOW.Com Content Network
Second-generation sulfonylureas have increased potency by weight, compared to first-generation sulfonylureas. [21] Similarly, ACCORD (Action to Control Cardiovascular Risk in Diabetes) [ 22 ] and the VADT (Veterans Affairs Diabetes Trial) [ 23 ] studies showed no reduction in heart attack or death in patients assigned to tight glucose control ...
Carbutamide (brand name Glucidoral) is an anti-diabetic drug of the sulfonylurea class, developed by Servier. It is classified as first-generation. [1] It was patented in 1953 and approved for medical use in 1956. [2]
2 Sulfonylureas (anti-diabetic agents) 3 Diuretics. 4 Anticonvulsants. 5 Dermatologicals. 6 Antiretrovirals. 7 Hepatitis C antivirals. 8 Stimulants. 9 NSAIDs. 10 ...
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. [7] It is used when dietary changes, exercise, and weight loss are not enough. [4] It is taken by mouth. [7] Side effect may include low blood sugar, vomiting, abdominal pain, rash, and liver problems.
Eight types of these pills have been marketed in North America, but not all remain available. The "second-generation" sulfonylureas are now more commonly used. They are more effective than first-generation drugs and have fewer side-effects. All may cause weight gain. [citation needed]
Tolbutamide is a first-generation potassium channel blocker, sulfonylurea oral hypoglycemic medication. This drug may be used in the management of type 2 diabetes if diet alone is not effective. Tolbutamide stimulates the secretion of insulin by the pancreas.
Chlorpropamide and other sulfonylureas encourage weight gain, so they are generally not favored for use in very obese patients. Metformin (Glucophage) is considered a better drug for these patients. Sulfonylureas should be used with caution or generally avoided in patients with hepatic and renal impairment, patients with porphyria , patients ...
Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. [1] It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).